Patents Assigned to Inotek Pharmaceutical Corporation
  • Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-YL)-3,4-dihydroxytetrahydrofuran-2-YL)] methyl nitrate and processes of preparation thereof
    Patent number: 9718853
    Abstract: The present invention provides novel anhydrous polymorph forms of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)]methyl nitrate (compound A), a selective adenosine A1 receptor agonist with a number of therapeutic uses including the treatment of elevated intra-ocular pressure. Also provided are methods for the preparation of the anhydrous polymorphic forms of compound A, pharmaceutical compositions and methods of treatment.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: August 1, 2017
    Assignee: Inotek Pharmaceuticals Corporation
    Inventor: William K. McVicar
  • Ophthalmic formulations
    Patent number: 9522160
    Abstract: The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 20, 2016
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: William K. McVicar, Harun Takruri
  • Combination, kit and method of reducing intraocular pressure
    Patent number: 9370530
    Abstract: The present invention is directed to a composition or a kit comprising a combination of a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 21, 2016
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Rudolf A. Baumgartner
  • Method of reducing intraocular pressure in humans
    Patent number: 9289383
    Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: March 22, 2016
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Prakash Jagtap
  • Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
    Patent number: 9278991
    Abstract: The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) methyl nitrate (Compound A), a selective adenosine A1 receptor agonist with a number of therapeutic uses including the treatment of elevated intra-ocular pressure. Also provided are methods for the preparation of the anhydrous polymorphic forms of compound A, pharmaceutical compositions and methods of treatment.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: March 8, 2016
    Assignee: Inotek Pharmaceuticals Corporation
    Inventor: William K. McVicar
  • Method of reducing intraocular pressure in humans
    Patent number: 8895530
    Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: November 25, 2014
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Prakash Jagtap
  • Combination, kit and method of reducing intraocular pressure
    Patent number: 8877732
    Abstract: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: November 4, 2014
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Rudolf A. Baumgartner
  • OPHTHALMIC FORMULATIONS
    Publication number: 20140271876
    Abstract: The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: INOTEK PHARMACEUTICALS CORPORATION
    Inventors: William K. MCVICAR, Harun TAKRURI
  • METHOD OF PROVIDING OCULAR NEUROPROTECTION
    Publication number: 20140275128
    Abstract: Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for preventing, reducing or treating retinal ganglion cell damage comprising administering an effective amount of a purine derivative to a subject in need thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: INOTEK PHARMACEUTICALS CORPORATION
    Inventor: William K. MCVICAR
  • METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS
    Publication number: 20140018314
    Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
    Type: Application
    Filed: June 4, 2013
    Publication date: January 16, 2014
    Applicant: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Prakash JAGTAP
  • Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
    Patent number: 8609833
    Abstract: The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: December 17, 2013
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Prakash Jagtap, Csaba Szabo, Andrew L. Salzman
  • METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS
    Publication number: 20130217643
    Abstract: Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for reducing intraocular pressure comprising administering an effective amount of compounds of Formula I to a subject in need thereof.
    Type: Application
    Filed: April 3, 2013
    Publication date: August 22, 2013
    Applicant: INOTEK PHARMACEUTICALS CORPORATION
    Inventor: INOTEK PHARMACEUTICALS CORPORATION
  • Adenosine compounds and their use thereof
    Patent number: 8501708
    Abstract: Provided herein are a class of purine nucleoside compounds, particularly substituted adenosine compounds, such as benzyloxy cyclopentyladenosine (BCPA) compounds, as well as methods of using these compounds as selective A1 adenosine receptor agonists, particularly for reducing and/or controlling elevated or abnormally fluctuating intraocular pressure (IOP) in the treatment of glaucoma or ocular hypertension (OHT).
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: August 6, 2013
    Assignee: Inotek Pharmaceuticals Corporation
    Inventor: Prakash Jagtap
  • ANHYDROUS POLYMORPHS OF [(2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL)} METHYL NITRATE AND PROCESSES OF PREPARATION THEREOF
    Publication number: 20130196940
    Abstract: The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate (Compound A). The present invention also provides processes for preparation of the anhydrous polymorphic forms of compound A.
    Type: Application
    Filed: January 25, 2013
    Publication date: August 1, 2013
    Applicant: INOTEK PHARMACEUTICALS CORPORATION
    Inventor: Inotek Pharmaceuticals Corporation
  • Method of reducing intraocular pressure in humans
    Patent number: 8476247
    Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: July 2, 2013
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley, Prakash Jagtap
  • Method of reducing intraocular pressure in humans
    Patent number: 8470800
    Abstract: Provided herein are compounds, compositions, and methods for reducing intraocular pressure. Also provided herein are compounds, compositions and methods for the treatment of glaucoma or ocular hypertension.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: June 25, 2013
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Shikha Barman, Rudolf A. Baumgartner
  • Combination compositions for reducing intraocular pressure
    Patent number: 8455457
    Abstract: Provided herein is a pharmaceutical composition or a kit comprising a combination of a non-selective beta-adrenergic receptor blocker and an adenosine A1 receptor agonist. Also provided herein is a method of reducing intraocular pressure (IOP) in a subject using such a combination or kit. In a particular embodiment, provided herein is a combination of timolol marketed under the brand Timoptic™ and Compound A.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: June 4, 2013
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley
  • Combination compositions for reducing intraocular pressure
    Patent number: 8440639
    Abstract: Provided herein is a pharmaceutical composition or a kit comprising a combination of a carbonic anhydrase inhibitor analog and an adenosine A1 receptor agonist. Also provided herein is a method of reducing intraocular pressure (IOP) in a subject using such a combination or kit. In a particular embodiment, provided herein is a combination of dorzolamide marketed under the brand Trusopt™ and Compound A.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: May 14, 2013
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Norman N. Kim, William K. McVicar, Thomas G. McCauley
  • PURINE DERIVATIVES AS ADENOSINE A1 RECEPTOR AGONISTS AND METHODS OF USE THEREOF
    Publication number: 20120264706
    Abstract: The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.
    Type: Application
    Filed: April 20, 2012
    Publication date: October 18, 2012
    Applicant: INOTEK PHARMACEUTICALS CORPORATION
    Inventors: Prakash JAGTAP, Csaba SZABO, Andrew L. SALZMAN
  • Antibodies against flagellin and uses thereof
    Patent number: 8263078
    Abstract: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: September 11, 2012
    Assignees: Inotek Pharmaceuticals Corporation, Yeda Research and Development Co., Ltd.
    Inventors: Nurit Rachamim, Andrew L. Salzman, Kanneganti Murthy